Tags: 
Join Dr. Keith Crawford and Dr. David Einstein, who was ranked among the top prostate cancer oncologists in the country by Newsweek in 2024 and is an investigator of the Phase 3 XALute trial, as he explains:
- What the study drug xaluritamig does to help the immune system fight prostate cancer
- What the XALute clinical trial is testing (xaluritamig vs. cabazitaxel)
- Who can qualify and how to join the study
The XALlute clinical trial is an important, ongoing research study exploring a new immunotherapy for people with advanced prostate cancer, and it may boost the immune system’s ability to fight this advanced cancer.
Wednesday, January 28th at 6:00 PM ET
Keith Crawford, MD, PhD
Director of Clinical Trials and Patient Education
PHEN
David Einstein, MD
Academic Medical Oncologist
Beth Israel Deaconess Medical Center
Featured Clinical Trial
This is a Phase 3 clinical study that tests xaluritamig versus cabazitaxel in men with metastatic castration-resistant prostate cancer (mCPRC) who were previously treated with chemotherapy.